66 related articles for article (PubMed ID: 20396797)
21. Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection.
Kimbrough CW; Beal EW; Dillhoff ME; Schmidt CR; Pawlik TM; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha FG; Crown A; Abbott DE; Fisher AV; Fields RC; Krasnick BA; Idrees K; Marincola-Smith P; Cho CS; Beems M; Maithel SK; Cloyd JM
Surgery; 2019 Mar; 165(3):657-663. PubMed ID: 30377003
[TBL] [Abstract][Full Text] [Related]
22. [Carcinoid syndrome in neuroendocrine tumors--not easy to recognize].
Milos B
Acta Chir Iugosl; 2013; 60(3):13-6. PubMed ID: 24669575
[TBL] [Abstract][Full Text] [Related]
23. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.
Halperin DM; Shen C; Dasari A; Xu Y; Chu Y; Zhou S; Shih YT; Yao JC
Lancet Oncol; 2017 Apr; 18(4):525-534. PubMed ID: 28238592
[TBL] [Abstract][Full Text] [Related]
24. Infection with multidrug-resistant Campylobacter coli mimicking recurrence of carcinoid syndrome: a case report of a neuroendocrine tumor patient with repeated diarrhea.
Lagler H; Kiesewetter B; Raderer M
BMC Infect Dis; 2016 Aug; 16():409. PubMed ID: 27519265
[TBL] [Abstract][Full Text] [Related]
25. Clinical and biochemical aspects of the carcinoid syndrome in neuroendocrine tumors of the abdominal and retroperitoneal organs and its impact for the disease prognosis.
Polikarpova SB; Lubimova NV; Ogereliev AS; Britvin TA; Davidov MI
Bull Exp Biol Med; 2009 Nov; 148(5):803-6. PubMed ID: 20396797
[TBL] [Abstract][Full Text] [Related]
26. [Pathological implications in the neuroendocrine gastrointestinal system].
Piette C; Polus M; Louis E
Rev Med Liege; 2002 Aug; 57(8):509-18. PubMed ID: 12405024
[TBL] [Abstract][Full Text] [Related]
27. Carcinoid syndrome and serotonin: therapeutic effects of ketanserin.
Robertson JI
Cardiovasc Drugs Ther; 1990 Jan; 4 Suppl 1():53-8. PubMed ID: 2285651
[TBL] [Abstract][Full Text] [Related]
28. Carcinoid syndrome: update on the pathophysiology and treatment.
Rubin de Celis Ferrari AC; Glasberg J; Riechelmann RP
Clinics (Sao Paulo); 2018 Aug; 73(suppl 1):e490s. PubMed ID: 30133565
[TBL] [Abstract][Full Text] [Related]
29. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract.
Rorstad O
J Surg Oncol; 2005 Mar; 89(3):151-60. PubMed ID: 15719376
[TBL] [Abstract][Full Text] [Related]
30. Carcinoid Syndrome: Preclinical Models and Future Therapeutic Strategies.
Vitale G; Carra S; Alessi Y; Campolo F; Pandozzi C; Zanata I; Colao A; Faggiano A; On Behalf Of The Nike Group
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835022
[TBL] [Abstract][Full Text] [Related]
31. Recent Advances in the Diagnosis and Management of Carcinoid Syndrome.
Subash N; Papali MM; Bahadur KP; Avanthika C; Jhaveri S; Thannir S; Joshi M; Valisekka SS
Dis Mon; 2022 Jul; 68(7):101304. PubMed ID: 34972546
[TBL] [Abstract][Full Text] [Related]
32. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
Guadalupe E; Deshpande HA; Stein SM
Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
[TBL] [Abstract][Full Text] [Related]
33. Carcinoid-syndrome: recent advances, current status and controversies.
Ito T; Lee L; Jensen RT
Curr Opin Endocrinol Diabetes Obes; 2018 Feb; 25(1):22-35. PubMed ID: 29120923
[TBL] [Abstract][Full Text] [Related]
34. Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome).
de Herder WW
Best Pract Res Clin Gastroenterol; 2005 Oct; 19(5):705-15. PubMed ID: 16253895
[TBL] [Abstract][Full Text] [Related]
35. Statistical evaluation of 2001 carcinoid cases with metastases, collected from literature: a comparative study between ordinary carcinoids and atypical varieties.
Soga J
J Exp Clin Cancer Res; 1998 Mar; 17(1):3-12. PubMed ID: 9646227
[TBL] [Abstract][Full Text] [Related]
36. Neuroendocrine tumors and fibrosis: An unsolved mystery?
Laskaratos FM; Rombouts K; Caplin M; Toumpanakis C; Thirlwell C; Mandair D
Cancer; 2017 Dec; 123(24):4770-4790. PubMed ID: 29112233
[TBL] [Abstract][Full Text] [Related]
37. Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea.
Masab M; Saif MW
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1055-1062. PubMed ID: 29051994
[TBL] [Abstract][Full Text] [Related]
38. Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications.
Fanciulli G; Ruggeri RM; Grossrubatscher E; Calzo FL; Wood TD; Faggiano A; Isidori A; Colao A;
Rev Endocr Metab Disord; 2020 Dec; 21(4):599-612. PubMed ID: 32152781
[TBL] [Abstract][Full Text] [Related]
39. [Neuroendocrine tumors of the kidneys].
Moch H
Pathologe; 2015 May; 36(3):278-82. PubMed ID: 25898936
[TBL] [Abstract][Full Text] [Related]
40. Carcinoid tumors and the carcinoid syndrome.
Feldman JM
Curr Probl Surg; 1989 Dec; 26(12):835-85. PubMed ID: 2701223
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
